Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.31 |
| ▸ | PGR | P06401 | 3/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.31 |
| ▸ | AR | P10275 | 3/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1351461 | 0.90 | PDE2A (0.40) | PDE2ACYP3A4SLC6A2SLC6A4NR3C1 | |
| SCHEMBL1349153 | 0.88 | NR3C1 (0.34) | SLC6A2SLC6A4NR3C1PGRNR3C2 | |
| SCHEMBL1347547 | 0.88 | KMT2A (0.36) | NR3C1PGRNR3C2ARADRA1A | |
| SCHEMBL1349920 | 0.87 | ADRA1A (0.32) | NR3C1ADRA1A | |
| SCHEMBL1351243 | 0.86 | PDE2A (0.34) | PDE2ACTSSNR3C1PGRNR3C2 | |
| SCHEMBL1351026 | 0.85 | PDE2A (0.38) | PDE2ASLC6A2SLC6A4MRGPRX4CRHR1 | |
| SCHEMBL1350303 | 0.82 | FPR2 (0.34) | CYP3A4NR3C1PGRNR3C2AR | |
| SCHEMBL1349900 | 0.80 | NR3C1 (0.39) | NR3C1PGRNR3C2ARADRA1A | |
| SCHEMBL1349863 | 0.80 | MRGPRX4 (0.33) | PDE2ACYP3A4CYP2C9CYP2C19MRGPRX4 | |
| SCHEMBL1349114 | 0.79 | SOS1 (0.32) | NR3C1PGRNR3C2ARADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063234-B2 | Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-22 | — | — | US | disclosed |
| US-8063234-B2 | Substituted 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindoles and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-22 | — | — | US | disclosed |
| US-20110201564-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201564-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201564-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2300423-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-30 | — | — | EP | disclosed |
| US-20100105744-A1 | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20100105744-A1 | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | US | disclosed |
| WO-2009156072-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156072-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105744-A1 | SUBSTITUTED 7-SULFANYLMETHYL-, 7-SULFINYLMETHYL- AND 7-SULFONYLMETHYLINDOLES AND THE USE THEREOF | STS, HTR7, PCSK7 | PDE2A 1593/4885CYP3A4 730/4885CYP2C9 915/4885 |
| US-20110201564-A1 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF | HTR7, STS, INMT | PDE2A 1601/4885CYP3A4 531/4885CYP2C9 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.